By delving into the mechanisms of AS-IV, this study elucidates how it weakens PD-L1-mediated immune suppression through the miR-135b-5p/CNDP1 axis, potentially representing a key mechanism for AS-IV in anti-hepatocellular carcinoma (HCC) therapy. The gene discussed is CNDP1; the disease is hepatocellular carcinoma.